Biomea Fusion, Inc. 今日宣布，其Opal临床研究已成功完成首例患者给药。该研究旨在评估Icovamenib与司美格鲁肽联合用药方案在肥胖症治疗中的潜力。这一里程碑事件，标志着公司在该领域的探索迈出了关键一步。
Biomea Fusion, Inc. 今日宣布，其Opal临床研究已成功完成首例患者给药。该研究旨在评估Icovamenib与司美格鲁肽联合用药方案在肥胖症治疗中的潜力。这一里程碑事件，标志着公司在该领域的探索迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.